



## **Akebia Therapeutics to Participate in Upcoming Investor Conferences**

November 20, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 20, 2018-- [Akebia Therapeutics](#), Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that it will participate in the following investor conferences:

- The 30<sup>th</sup> Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018, at 12:30 p.m. Eastern Time at the Lotte New York Palace Hotel. Akebia will participate in a fireside chat discussion; and
- The Global Mizuho Investor Conference on Monday, December 3, 2018, at the Lotte New York Palace Hotel.

A replay of the webcast from the Piper Jaffray Healthcare Conference will be available on the company's website at [www.akebia.com](http://www.akebia.com) the day following the conference. To access, please log onto the Akebia website at least 15 minutes prior to the webcast to ensure adequate time for any software downloads that may be required.

### **About Akebia Therapeutics**

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. For more information, please visit our website at [www.akebia.com](http://www.akebia.com), which does not form a part of this release.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20181120005661/en/>

Source: Akebia Therapeutics, Inc.

John Garabo  
Director, Corporate Communications  
617-844-6130  
[jgarabo@akebia.com](mailto:jgarabo@akebia.com)